Becton Dickinson (NYSE: BDX) raised its adjusted earnings per share (EPS) guidance for fiscal year 2026, signaling stronger-than-expected profitability. The medical technology company increased the lower bound of its EPS forecast from $12.52 to $12.62, while maintaining the upper bound at $12.72. This revised outlook now sits above the consensus analyst estimate of $12.61, reflecting improved operational confidence or favorable market conditions.

The adjustment represents a meaningful upgrade in investor expectations for the period. By lifting the floor of its guidance range by $0.10, Becton Dickinson indicates that recent performance trends support a more robust earnings trajectory than previously communicated. The upper end of the range remains unchanged at $12.72, suggesting that while downside risks have been mitigated, the company sees limited immediate upside potential beyond its initial ceiling.

Guidance Revision Details

The following table outlines the changes in Becton Dickinson’s FY2026 adjusted EPS guidance:

What the Numbers Show

The revision is notable because it not only tightens the company’s own expectations but also beats external market forecasts. With the new lower bound of $12.62 exceeding the analyst estimate of $12.61, Becton Dickinson has effectively removed the risk of missing consensus expectations on the low end. This alignment suggests that management’s internal models are now converging with, or slightly outperforming, Wall Street’s projections for the fiscal year. The stability of the upper bound at $12.72 implies that the primary driver of this change was a reduction in perceived downside risk rather than a discovery of new upside catalysts.

The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.05 per common share, signaling continued commitment to shareholder returns. The dividend is payable on September 30, 2026, to holders of record as of September 9, 2026. This announcement ensures that eligible shareholders will receive their distribution on the specified date, maintaining the company's indicated annual dividend rate of $4.20 per share.

Dividend Details

The key dates and figures for this dividend distribution are outlined below:

Shareholders must hold BD common stock by the close of business on the record date to be eligible for the payment. The company did not disclose any changes to its broader capital allocation strategy alongside this routine quarterly declaration.

About BD

BD is a leading global medical technology company focused on advancing health through innovation in medical essentials, connected care, biopharma systems, and interventional solutions. With more than 60,000 employees worldwide, the company delivers billions of products annually aimed at optimizing clinical operations and improving patient care outcomes.